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INTRODUCTION
Colorectal cancer (CRC) is currently one of the most preva-
lent malignant diseases (Siegel et al., 2019). While the prima-
ry tumor is commonly resected, dissemination of the primary 
malignancy to distant organs worsens prognosis, with the liver 
being the most common target organ for CRC cells (van der 
Pool et al., 2012). Such a scenario further complicates treat-
ment strategies and, thus, negatively impacts life expectancy. 
Therefore, understanding the organ-specific prometastatic 
events that occur in tumor colonization of the liver arises as 
one of the most urgent requirements for coping with this dis-
ease.
CRC cell invasion of the liver starts at the hepatic sinu-
soids—narrow, sinuose, and highly specialized capillaries 
composed of hepatic-specific non-parenchymal cell types, 
such as liver sinusoidal endothelial cells (LSECs), resident 
macrophages (also known as Kupffer cells (KC)), and peri-
cyte-like hepatic stellate cells (HSCs). The interaction of CRC 
cells with LSECs via adhesion molecules is one of the earliest 
events that initiate the prometastatic cascade. As a result, a 
proinflammatory and proangiogenic microenvironment is gen-
erated (Khatib et al., 2002; Arteta et al., 2010). 
Intercellular adhesion molecule-1 (ICAM-1) is one of the 
adhesion molecules proposed as a key factor triggering this 
initial response. ICAM-1 is constitutively expressed in LSECs 
and is upregulated under inflammatory conditions (Volpes et 
al., 1990; Benedicto et al., 2019). We have previously shown 
a reduction in the metastatic burden of the liver when prevent-
ing tumor lymphocyte function associated antigen-1 (LFA-1) 
for interacting with its ligand, ICAM-1, on LSECs in an experi-
mental metastatic model of CRC cells (Benedicto et al., 2017, 
2019).
In the early phases of experimental liver colonization of CRC 
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Liver colonization is initiated through the interplay between tumor cells and adhesion molecules present in liver sinusoidal endo-
thelial cells (LSECs). This crosstalk stimulates tumor COX-2 upregulation and PGE2 secretion. To elucidate the role of the LSEC 
intercellular adhesion molecule-1 (ICAM-1) in the prometastatic response exerted by tumor and stromal COX-2, we utilized cele-
coxib (CLX) as a COX-2 inhibitory agent. We analyzed the in vitro proliferative and secretory responses of murine C26 colorectal 
cancer (CRC) cells to soluble ICAM-1 (sICAM-1), cultured alone or with LSECs, and their effect on LSEC and hepatic stellate cell 
(HSC) migration and in vivo liver metastasis. CLX reduced sICAM-1-stimulated COX-2 activation and PGE2 secretion in C26 cells 
cultured alone or cocultured with LSECs. Moreover, CLX abrogated sICAM-1-induced C26 cell proliferation and C26 secretion of 
promigratory factors for LSECs and HSCs. Interestingly, CLX reduced the protumoral response of HSC, reducing their migratory 
potential when stimulated with C26 secretomes and impairing their secretion of chemotactic factors for LSECs and C26 cells and 
proliferative factors for C26 cells. In vivo, CLX abrogated the prometastatic ability of sICAM-1-activated C26 cells while reducing 
liver metastasis. COX-2 inhibition blocked the creation of a favorable tumor microenvironment (TME) by hindering the intratumoral 
recruitment of activated HSCs and macrophages in addition to the accumulation of fibrillar collagen. These results point to COX-2 
being a key modulator of processes initiated by host ICAM-1 during tumor cell/LSEC/HSC crosstalk, leading to the creation of a 
prometastatic TME in the liver.
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cells, ICAM-1 prompts the secretion of different inflammatory 
mediators, such as IL-1β, IL-6, PGE2, and TNF-α (Benedicto 
et al., 2019). Interestingly, cyclooxigenase-2 (COX-2), the lim-
iting enzyme in the synthesis of PGE2, is one of the intracellu-
lar mediators of several inflammatory molecules (Greenhough 
et al., 2009) and it has been related to CRC and disease pro-
gression. In this regard, Shoji et al. (2003) showed that the 
implantation of CRC xenografts increased COX-2 expression 
in cancer cells, while elevated COX-2 expression in human 
malignant tissue was related to lymph node and liver metas-
tasis (Yu et al., 2005). Several studies showed that COX-2 
inhibition reduces the metastatic spread of CRC cells (Chen 
et al., 2001; Nagatsuka et al., 2002; Yao et al., 2004). In recent 
years, COX-2 inhibitors have been postulated as good candi-
dates for the treatment of liver metastasis in combination with 
antiangiogenic drugs (Xu et al., 2014). Increasing evidence in-
dicates that recruitment of host cells to developing metastatic 
foci are key in the secretion of proangiogenic vascular endo-
thelial growth factor (VEGF) through their interaction with can-
cer cells and, therefore, the promotion of tumor growth (Olaso 
et al., 2003; Benedicto et al., 2019). 
Despite this plethora of information, little is known about the 
role of COX-2 as a major force in the creation of the proinflam-
matory and proangiogenic microenvironment that boosts tu-
mor progression during liver metastasis by means of resident 
cell recruitment. In this study, we aimed to shed some light 
on the ICAM-1-dependent COX-2-driven mechanisms during 
cancer cell/LSEC crosstalk in the early stage of liver coloniza-
tion. Furthermore, we analyzed, for the first time, the COX-
2 dependence of the prometastatic response of HSCs in the 
hepatic microenvironment generated by colonizing CRC cells.
MATERIALS AND METHODS
Animals
BALB/c mice, 6-8 weeks old, were obtained from Charles 
River (Barcelona, Spain). Maintenance, care, and experimen-
tal conditions were developed under institutional guidelines 
and national laws for experimental animal care. All of the pro-
ceedings were approved by the Basque Country University 
Ethical Committee (CEID) in accordance with institutional, 
national, and international guidelines regarding the protection 
and care of animals used for scientific purposes.
Cell lines
In vivo assays were conducted using murine C26 colon ad-
enocarcinoma cell line, syngenic with BALB/c, that was ob-
tained from ATCC (LGC Standards S.L.U., Barcelona, Spain). 
In addition, for the in vitro experiments, mouse origin NIH 
3T3 fibroblast and J774A.1 macrophage cell lines were used, 
both obtained from ATCC. All of the cells lines were cultured 
under standard conditions, C26 in RPMI-1640, NIH 3T3 in 
DMEM/F-12, and J774A.1 in DMEM, all of which were supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 
penicillin (100 U/mL), streptomycin (100 µL), and amphotericin 
B (25 µg/mL; Thermo Fisher Scientific, Waltham, MA, USA).
C26 secretomes 
Tumor cell secretomes were obtained by culturing 5.3×104 
C26 tumor cells/cm2 on 24-wells plates in complete RPMI-
1640 medium overnight. Then, the media was replaced with 
fresh serum-free RPMI-1640 medium. After 24 h of incubation, 
the media was collected and centrifuged at 4000 rpm for 5 
min for the collection of C26 secretome. For COX-2 inhibition, 
cells were treated for 1 h with 20 µM celecoxib (CLX; Sigma-
Aldrich, St. Louis, MO, USA) in 1% FBS containing RPMI-
1640. Afterwards, the cells were activated as indicated with 
sICAM-1 (200 ng/mL; Life Technologies, Carlsbad, CA, USA) 
in 1% FBS containing RPMI-1640 for 18 h. Finally, the me-
dium was replaced with serum-free RPMI-1640 medium and 
collected after 24 h, followed by 4000 rpm centrifugation for 5 
min, and the supernatant was stored at −20ºC.
Isolation and culture of primary LSECs and HSCs 
The isolation and culture of mouse LSECs and HSCs have 
been described elsewhere (Smedsrod and Pertoft, 1985). 
Briefly, livers were perfused using collagenase type IV, dis-
aggregated, and were subjected to isopycnic centrifugation 
using a Percoll gradient (GE Healthcare, Chicago, IL, USA). 
KCs were removed by differential adhesion onto plastic. The 
obtained LSECs were cultured onto 24-well plates coated 
with 0.05 mg/mL collagen type I (Thermo Fisher Scientific) at 
1.6×106 cell/mL in RPMI-1640 supplemented with 5% FBS. 
LSECs were incubated for at least 2 h at 37ºC prior to the 
start of experiments. HSCs were cultured in RPMI-1640 in un-
coated plates for 18 h before experimentation. For the COX-2 
inhibition assays, HSCs were treated with 20 µM CLX for 1 h 
before adding any treatment routine. C26 were pretreated with 
20 µM CLX before sICAM-1 activation before their addition to 
LSEC cultures.
Establishment of LSEC cocultures with C26 tumor cells 
After isolation, LSECs were incubated for 3 h with RPMI-
1640 supplemented with 5% FBS before experimentation. 
Next, the C26 cells were added to a 1:5 LSEC/tumor cell ratio 
with RPMI-1640 supplemented with 1% FBS for 6 h. In some 
experiments, the tumor cells were subjected to either ICAM-1 
stimulation, COX-2 inhibition, or both before tumor cell addi-
tion to LSEC cultures.
ELISA assays 
The presence of PGE2 and VEGF were analyzed through 
an enzyme-linked immunosorbent assay (ELISA) in cell cul-
ture supernatants following the manufacturer’s instructions 
(R&D Systems, Minneapolis, MN, USA). 
COX-2 activity measure 
For the quantification of COX-2 activity, either cell mono-
cultures or cocultures treated under the different experimental 
conditions were incubated for 30 min in the presence of ara-
chidonic acid (10 µM), and the culture supernatant was col-
lected for the analysis of PGE2 through ELISA.
Proliferation assay 
For measurement of tumor cell proliferation, 1.56×104 tu-
mor cells/cm2 were cultured for 24 h. Cells were treated with 
20 µM CLX for 1 h. The media was changed to fresh media 
containing 1% FBS and supplemented with increasing con-
centrations of sICAM-1, ranging from 50 up to 200 ng/mL. Cell 
proliferation was measured after 24 and 48 h using an MTT 
assay (Sigma-Aldrich).
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Transwell migration assay 
For the transwell migration assay, 2×104 cells/transwell of 
either LSECs or HSCs were cultured for 3 h in type I collagen-
coated modified Boyden chambers (Greiner BioOne, Krems-
münster, Austria). Afterward, the cells were stimulated with dif-
ferent secretome preparations for 18 h before analysis of the 
cell migration. The inserts were cut off, fixed in 4% PFA, and 
stained with crystal violet (Sigma-Aldrich). For the quantifica-
tion, 5-10 images were obtained at 200× magnification from 
each insert and were counted using ImageJ software (NIH, 
Bethesda, MD, USA). 
Wound healing assay 
Fibroblasts and macrophages were cultured overnight at 
2×105 cells/mL on 24-well plates in DMEM-F12 and DMEM 
medium, respectively, supplemented with 10% FBS. The next 
day, cells were treated with mitomycin C (Fisher Scientific, 
Thermo Fisher Scientific; 5 µg/mL for fibroblasts and 1 µg/mL 
for macrophages) for 2 h. Afterwards, a scratch or wound was 
created using a 200 µL tip, and the medium was replaced with 
C26 secretome obtained after different treatments, diluted at 
a ratio of 1:2 in fresh RPMI, and supplemented with 1% FBS. 
Pictures were taken at 0 and 24 h. Quantification was carried 
out using ImageJ software (NIH) through the measurement of 
total wound area after 24 h compared with that at 0 h. 
Experimental development of hepatic metastasis 
A total of 2×105 tumor cells diluted in PBS were injected 
intrasplenically (i.s.) in BALB/c mice anesthetized with Nem-
butal (50 mg/kg). The mice were randomly separated into four 
groups as follows: control tumor-bearing mice group, control 
tumor-bearing CLX-treated mice group, sICAM-activated tu-
mor-bearing mice group, and sICAM-activated tumor-bearing 
CLX-treated mice group. CLX was administered daily through 
oral cleavage for 14 d (100 µg/kg). Then, the livers were col-
lected and fixed in a zinc solution and embedded in paraffin for 
histological analysis. The metastatic liver area occupied by the 
tumor was quantified through H&E staining in 5 µm thick liver 
sections. Furthermore, the collagen deposition was analyzed 
through Picrosirius Red staining. All in vivo experiments were 
carried out twice with a minimum of 5 mice per experimental 
group.
Immunohistochemical assays 
Recruitment of the host cells was analyzed in the liver tis-
sue by immunohistochemical analysis through alpha-smooth 
muscle actin (ASMA) and F4/80 labeling for HSCs and mac-
rophages, respectively. For ASMA staining, 5 µm liver tissue 
sections were incubated at 95ºC for 30 min in a citrate buffer 
(pH 6.0) for antigen retrieval. Next, endogenous peroxidase 
was blocked through 40 min of incubation in 3% H2O2 contain-
ing 1× PBS, followed by 1 h of incubation in 5% FBS con-
taining 1× PBS. Then, the samples were incubated with F(ab) 
antibody to inhibit unspecific binding, followed by overnight 
incubation with the mouse anti-human ASMA antibody (1:500; 
DakoCytomation, Agilent Technologies, Santa Clara, CA, 
USA). Next, the samples were washed with 1× PBS, incubat-
ed with rat anti-mouse secondary antibody (1:500; Invitrogen, 
Thermo Fisher Scientific), and visualized through HRP (1:500) 
and DAB Quanto substrate (Thermo Fisher Scientific). For the 
F4/80 staining, antigen retrieval was carried out by incubating 
the samples with 100 µL of proteinase K (final concentration 
1.2 U/mL; Sigma-Aldrich) diluted in 1 mL of TE buffer (0.5% 
Triton X-100 diluted in 50 mM Tris with 1 mM EDTA). After per-
oxidase and unspecific binding blocking, as described above, 
the liver tissue sections were incubated overnight with rat anti-
mouse F4/80 primary antibody (1:200; Bio-Rad, Hercules, 
CA, USA). After incubation with a biotin-conjugated secondary 
goat-anti rat antibody (1:500; Invitrogen, Thermo Fisher Sci-
entific), the process proceeded as described above. 
Statistical analyses 
Data are expressed as mean ± standard deviation (SD) of 
three independent experiments. The statistical analysis was 
performed using SPSS version 13.0 (Professional statistic, 
Chicago, IL, USA). Individual comparisons were performed 
using a two-tailed, unpaired Student’s t-test. 
RESULTS
COX-2 inhibition impairs tumor cell proliferation 
mediated by ICAM-1 
The enhancement of uncontrolled tumor growth provided 
by the host microenvironment is a hallmark of metastasis. We 
have previously shown that C26 cell colonization of the liver 
correlates with ICAM-1 upregulation on LSECs (Arteta et al., 
2010; Benedicto et al., 2019). The interplay between metastat-
ic C26 cells and LSECs in the liver sinusoids was mimicked 
by stimulating C26 cells with sICAM-1 for up to 48 h. sICAM-1 
heightened C26 cell proliferation by nearly two-fold after 24 
h, and was maintained for the following 24 h. Interestingly, 
COX-2 inhibition by CLX uncovered that this early tumor re-
sponse to sICAM-1 is partly dependent on tumor COX-2 (Fig. 
1). COX-2 inhibition exerted a discrete effect on the basal pro-
liferation of C26 cells after 24 h, while completely abrogated 
sICAM-1-stimulated C26 cell proliferation. However, after 48 
h, both the basal and sICAM-1-induced proliferation of C26 
cells was inhibited.
CRC cell interaction with LSECs drives tumor COX-2 
synthesis of PGE2 through endothelial ICAM-1 
Early steps of liver colonization occur in the liver sinusoids, 
and the interaction of tumor cells with LSECs represent a lim-
iting step for the development of liver metastasis. Our group 
has previously shown that this interaction is highly dependent 
on ICAM-1 (Arteta et al., 2010; Benedicto et al., 2019). We 
revealed that C26 activation by sICAM-1 induced a stimula-
tion similar to that observed after direct interaction with LSECs 
(Arteta et al., 2010). Here, we show that tumor cells increase 
the secretion of the proinflammatory mediator PGE2 upon 
sICAM-1 activation in a COX-2-dependent manner (Fig. 2A, 
2B). In line with this approach, coculture experiments of tu-
mor cells and freshly isolated primary LSECs revealed similar 
results, with a two-fold PGE2 enhancement in the C26–LSEC 
coculture secretomes (Fig. 2C). The PGE2 increase was paral-
leled by a substantial two-fold upregulation in COX-2 activity 
(Fig. 2D). Interestingly, CLX downregulated both COX-2 activi-
ty and PGE2 secretion in sICAM-1-activated C26 cells cultured 
alone or in coculture with LSECs. Therefore, tumor cell COX-2 
and PGE2 production may represent a key mediator during the 
interplay between C26 cancer cells and LSECs, representing 
the starting point for early liver colonization of CRC. 
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C26 cells increase the migratory potential of LSECs and 
HSCs via tumor COX-2 
The recruitment of LSECs and HSCs is a crucial event for 
the establishment and growth of experimental CRC tumors 
(Vidal-Vanaclocha, 2011). We have previously shown that 
C26 secretomes promote LSEC and HSC migration, and that 
sICAM-1 pretreatment of tumor cells enhanced this effect 
(Benedicto et al., 2019). Fig. 3 shows that the promigratory ef-
fect exerted by tumor cells on LSECs and HSCs is partly medi-
ated by tumor COX-2. Thus, tumor cell pretreatment with CLX 
reverted the increased migration of C26-secretome-treated 
LSECs and HSCs compared with that of untreated LSECs and 
HSCs. Hence, COX-2 arises as a regulator of the interaction 
between tumor cells and hepatic non-parenchymal cells. As 
mentioned before, this mechanism may account for the initial 
response of sinusoidal cells to the tumor, which is a limiting 
step for metastatic colonization of the liver by CRC in vivo.
To further confirm the involvement of COX-2 on the pro-
migratory effect exerted by sICAM-1-activated C26 cells, we 
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Fig. 1. Effect of COX-2 inhibition on tumor cell proliferation. The effect of COX-2 inhibition was analyzed in untreated colorectal cancer (CRC) 
cells and upon stimulation with recombinant sICAM-1 for 24 and 48 h, untreated or treated with 20 µM celecoxib (CLX). Tumor cells were 
treated with CLX for 1 h and stimulated with sICAM-1 for 24 and 48 h. Cell viability was quantified through MTT assay in three independent 
experiments. The differences between untreated and sICAM-1 stimulated cells were considered statistically significant at *p<0.05 using 
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Fig. 2. Measurement of PGE2 secretion and COX-2 activity in cell cultures. (A, B) C26 monocultures were stimulated with 200 ng/mL sI-
CAM-1 and treated with 10 and 20 µM CLX for the analysis of PGE2 production and COX-2 activity. (C, D) For the coculture experiments, 
C26 cells were treated with CLX before culturing them with freshly isolated primary LSECs for 6 h. Afterwards, the supernatants were col-
lected and analyzed for PGE2 concentration and COX-2 activity using ELISA and arachidonic acid metabolization, respectively. Differences 
between untreated and sICAM-1-stimulated cells were considered statistically significant at *p<0.05 using Student’s t-test. Differences be-
tween CLX-untreated versus CLX-treated cells were considered significant at #p<0.05 and ##p<0.01 using Student’s t-test.
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populations, NIH 3T3 fibroblasts and J774A.1 macrophage-
like cells. As observed in Fig. 3B, 3C, both cell lines respond-
ed similarly, as did primary LSECs and HSCs. Afresh, tumor 
cell COX-2 inhibition reduced the ability of C26 secretomes to 
promote the migration of both cell lines (Fig. 3C, 3D), as noted 
for primary LSECs and HSCs.
The prometastatic response of HSC is COX-2-dependent 
Although the role of COX-2 in tumor cells has been exten-
sively studied, the involvement of hepatic COX-2 activity dur-
ing liver metastasis remains mostly unexplored. As HSCs are 
recruited by tumor cell secretomes to liver foci shortly after 
their establishment (Olaso et al., 1997), we next analyzed the 
effect of COX-2 inhibition on the migratory potential of HSCs. 
As shown in Fig. 4A, the inhibition of HSC COX-2 by CLX abro-
gated both basal and C26 secretome-induced HSC migration. 
As previously reported (Olaso et al., 2003), tumor-activated 
HSCs promote LSEC migration. Interestingly, COX-2 inhibi-
tion in HSCs reduced the ability of C26secretome-activated 
HSCs to stimulate LSEC migration, reducing LSEC migration 
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Fig. 3. The effect of COX-2 inhibition in tumor-mediated liver sinusoidal endothelial cell (LSEC) and hepatic stellate cell (HSC) migration. (A, 
B) Freshly isolated primary LSECs and HSCs were cultured in modified Boden chambers and were stimulated with either C26 secretomes 
or CLX-treated C26 secretomes for 24 h. Afterwards, the inserts were fixed and stained with crystal violet for the quantification of migrated 
LSECs and HSCs. (C, D) NIH 3T3 and J774.1 were plated in 24-well plates and stimulated with C26 or CLX-treated C26 secretomes for 24 
h after creating a scratch. Closure of this area by each cell line was quantified through ImageJ software. Differences between the control 
cells versus C26-secretome-stimulated cells were considered statistically significant at *p<0.05 and **p<0.01 using Student’s t-test. Differ-


















































































































Fig. 4. Analysis of HSCs’ protumoral effect upon COX-2 inhibition. COX-2 was inhibited in freshly isolated primary HSCs, and several pro-
cesses linked with tumor progression were analyzed. CLX-treated HSCs were stimulated with C26 secretomes and their migration was ana-
lyzed (A). HSCs were treated with CLX and stimulated with C26 secretomes. Afterwards, soluble factors released by HSCs were collected. 
The migration of LSECs (B), C26 (C), and the proliferation of C26 (D) was measured in response to CLX-treated and C26-secretome-acti-
vated HSCs secretomes. Differences between untreated versus HSCs or C26-secretome-activated cells were considered statistically signifi-
cant at *p<0.05 and **p<0.01 using Student’s t-test. Differences between HSC or C26-secretome-stimulated HSCs versus CLX-treated HSC 
or C26-secretome-stimulated HSC-treated cells were considered significant at #p<0.05 and ##p<0.01 using Student’s t-test.
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to basal levels (Fig. 4B). Regarding the tumor response, HSCs 
stimulated the migration and proliferation of C26 cells by 4- 
and 5-fold, respectively (Fig. 4C, 4D). This effect was dramati-
cally reduced when COX-2 was inhibited in HSCs. Interest-
ingly, pre-activation of HSCs with C26 secretomes increased 
the stimulatory ability of HSC in the migration and proliferation 
of tumor cells. In line with previous results, the inhibition of 
COX-2 in C26-secretome-activated HSCs abrogated protu-
moral effect of HSCs on C26 cells (Fig. 4C, 4D). 
 ICAM-1 pretreatment of CRC cells boosts liver metastasis 
through COX-2 
Next, we investigated the role of sinusoidal endothelium-
derived ICAM-1 and the subsequent increase in COX-2 activ-
ity in tumor cells during experimental liver metastasis of CRC. 
To mimic the activation of tumor cells when interacting with 
LSEC ICAM-1, tumor cells were treated with sICAM-1 prior to 
their injection into mice.
We have previously demonstrated that in vitro sICAM-1 
pretreatment increases the metastatic potential of C26 cells 
(Benedicto et al., 2019). Fig. 5A shows the in vivo adminis-
tration of CLX to block tumor microenvironment development 
due to COX-2-impaired C26 cell liver metastasis compared 
with untreated C26 cells. Interestingly, CLX reduced the meta-
static burden in the livers of mice injected with either C26 cells 
or sICAM-1 preactivated C26 cells (Fig. 5A), thereby eliminat-
ing the sICAM-1-mediated increased aggressiveness of tumor 
cells. As observed in Fig. 5B, CLX inhibited tumor growth inde-
pendent of the tumor foci developmental status, ranging from 
avascular microfoci to larger ones that were at the vascular 
stage of growth. CLX also reduced the total area occupied by 
different size foci.
Interestingly, tumor microenvironment COX-2 inhibition re-
duced both the PGE2 and VEGF concentrations in the portal 
blood serum of tumor-bearing mice 14 days after tumor cell 
injection (Supplementary Fig. 2). It is worth noting that, at this 
late stage of tumor progression, COX-2 inhibition led to the 
restoration of portal PGE2 levels to those observed in healthy 
animals. Even though the effects on the portal VEGF concen-
tration were less notorious, they were shown to be significant 
14 days after tumor cell injection into mice treated with CLX. 
COX-2 blockade reduces the protumorigenic 
microenvironment promoted by the ICAM-1 stimulation 
of C26 cells 
Next, we analyzed whether CLX inhibition modified the stro-
mal compartment of metastatic foci. In line with our previous 
work (Benedicto et al., 2019), the pre-stimulation of C26 cells 
with sICAM-1 increased the recruitment of ASMA expressing 
cells to metastatic foci developed in the livers by 50%, the 
majority of them being activated HSCs (Raza et al., 2010), 
compared with those observed in the livers of mice injected 
with untreated cells. In line with the in vitro observations, the 
COX-2 blockade abrogated this effect, restoring the numbers 
of ASMA-positive cells recruited to metastatic foci back to 
those numbers observed in the livers from control mice (Fig. 
6A). A similar phenomenon was reported regarding tumor foci 
infiltration by F4/80 positive macrophages (Fig. 6B). Next, we 
analyzed fibrillar collagen accumulation as a sign of the des-
moplastic response developed during C26 tumor progression. 
Collagen synthesis within the tumor stroma was stimulated 
two-fold in the metastatic foci present in the livers collected 
from mice injected with sICAM-1-activated C26 cells. Interest-
ingly, COX-2 inhibition reversed the synthesis of fibrillar colla-
gen to the levels observed in the metastatic foci of basal C26-
injected mice (Fig. 6C). The reduction in the tumor stromal 
compartment and the stromal-mediated extracellular matrix 
(ECM) reorganization within the metastatic foci was correlated 
with tumor foci size.
DISCUSSION 
COX-2 has been linked with CRC and with the metastatic 
spread of cancer cells to the liver (Yu et al., 2005). However, 
little is known about the regulation of this enzyme during the 
early steps of liver colonization and how it influences the liver 
prometastatic response. In this study, we uncovered the rele-
vance of tumor COX-2 as a catalyst of the protumoral cascade 
mediated by ICAM-1 during tumor cell/LSEC crosstalk. To 
demonstrate this, we implemented in vitro approaches using 
freshly isolated LSECs and HSCs in order to achieve the most 



































































Fig. 5. Liver metastasis development in response to sICAM-1 stimulation and COX-2 blockade. C26 tumor cells were stimulated or not with 
sICAM-1, and injected in the distal pole of the spleen in mice. Mice were treated with oral cleavage of CLX for 14 days, and the develop-
ment of liver metastasis was quantified in terms of metastatic area and foci number and size (A, B). The levels of VEGF and PGE2 were 
analyzed in the plasma isolated from the portal blood seven and fourteen days after tumor cell injection into the control mice, C26-injected 
mice and C26-injected CLX-treated mice (C, D) (n=6). Differences in metastatic development between untreated C26 versus sICAM-1-treat-
ed C26 were considered statistically significant at *p<0.05 using Student’s t-test. Differences between CLX-untreated versus CLX-treated 
cells were considered significant at #p<0.05 and ##p<0.01 using Student’s t-test.
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periments of tumor cells and LSECs; migration assays of tu-
mor cells, LSECs, and HSCs under different conditions; and 
inhibited COX-2 in both cancer cells and HSCs using CLX. We 
confirmed the in vitro results using the in vivo orthotopic liver 
metastasis model of CRC. Cancer cells were activated with 
sICAM-1, and mice were treated with CLX to inhibit COX-2 
during metastatic development. We further analyzed the met-
astatic stromal compartment within the tumor foci, quantify-
ing the recruitment of ASMA expressing activated fibroblasts, 
F4/80-positive macrophages, and the accumulation of fibrillar 
collagen. Our results support the idea that after the interac-
tion of cancer cells with LSECs via ICAM-1, a prometastatic 
response is triggered in the liver, mediated not only by tumor 
COX-2 but also by COX-2 activity in HSCs (Fig. 7). 
We have previously shown that cancer cell interaction 
with LSEC ICAM-1 in the sinusoids promotes liver metasta-
sis. Here, we show that ICAM-1 seems to stimulate COX-2 in 
tumor cells, promoting cancer cell proliferation. Interestingly, 
COX-2 is the main mediator of PGE2, which is elevated in the 
blood plasma of cancer patients suffering from CRC liver me-
tastasis (Narisawa et al., 1990). In line with this report, our 
studies show that the first interaction between metastatic can-
cer cells and LSECs gives rise to increased COX-2 activity 
and subsequent PGE2 in an in vitro setting. This result was 
further confirmed by the sICAM-1 stimulation of cancer cells. 
It is well known that during metastatic growth, cancer cells 
recruit stromal cells to create a favorable microenvironment 
for tumor progression (Brodt, 2016). In the liver, this is rep-
resented by the recruitment of HSCs and LSECs into the 
nascent foci. Here, we show that COX-2 activation in cancer 
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Fig. 6. Differences in intratumor stromal compartment of liver metastasis in sICAM-1- and CLX-treated mice. The infiltration of ASMA- and 
F4/80-expressing cells was quantified in the metastatic foci of mice under different treatment routines (A, B). Furthermore, the accumulation 
of intratumoral fibrillar collagen was analyzed (C) (n=6). Differences between the untreated C26 versus sICAM-1-treated C26 cell intratu-
moral expression of ASMA, F4/80, and collagen were considered statistically significant for *p<0.05. Differences between CLX-untreated 
versus CLX-treated animals were considered significant at #p<0.05 and ##p<0.01 using Student’s t-test.
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cells promotes the secretion of attractant soluble factors that 
induce the migration of LSECs and HSCs. Interestingly, it has 
been reported that endothelial cell migration and tube forma-
tion is stimulated by PGE2. This finding may explain the re-
ported reduction in LSEC migration when these cells are stim-
ulated with CLX-treated C26 secretomes (Jana et al., 2016; 
Khan et al., 2019). Moreover, COX-2 mediates the secretion 
of VEGF (Supplementary Fig. 1; Cianchi et al., 2005; Toomey 
et al., 2009), a potent promigratory factor for both LSECs and 
HSCs. Thus, COX-2 inhibition may account for the reduced 
migration of HSCs and LSECs in vitro and for recruitment to 
the metastatic foci in vivo. Among the recruited liver-resident 
cells, HSCs are involved in angiogenesis by secreting VEGF 
under hypoxic conditions, driving LSEC recruitment and ac-
tivation (Olaso et al., 2003). Furthermore, HSCs are the pri-
mary source of fibrillar collagen in the liver, which makes them 
a good target for anti-fibrotic therapies (Puche et al., 2013). 
Moreover, HSCs express COX-2, which is upregulated during 
hypoxic conditions. Here, we show that COX-2 inhibition re-
duced the migration of C26-secretome-activated HSCs. COX-
2 inhibition by CLX could, in turn, reduce Akt activity on HSCs 
(Paik et al., 2009), which could impair HSC migration, given 
that Akt is involved in this process (Zhang et al., 2020). 
Interestingly, COX-2 inhibition decreased the ability of C26-
secretome-activated HSCs to promote LSEC and C26 cell 
migration. This effect could be linked with the reduced VEGF 
secretion by CLX-treated HSCs, as VEGF mediates the mi-
gration of LSECs and CRC cells (Valcárcel et al., 2008; Bhat-
tacharya et al., 2017; Benedicto et al., 2019). Furthermore, 
VEGF reduction in CLX-treated HSCs may also explain their 
impaired ability to promote C26 cell proliferation compared 
with that of C26-secretome-activated HSCs, as this mediator 
increases gastric cancer cell proliferation (Ma et al., 2019).
In concordance with our in vitro data, the analysis of in vivo 
liver metastasis by ICAM-1-activated C26 cells followed the 
same reduction trend under CLX treatment. In line with our pre-
vious reports, sICAM-1 pretreatment of tumor cells increased 
metastatic growth in the liver. Interestingly, COX-2 inhibition 
not only reduced liver colonization by untreated C26 cells but 
also diminished the prometastatic effect of those treated with 
sICAM-1. In the tumor microenvironment, a decrease in PGE2 
and VEGF levels in CLX-treated mice, which may be derived 
from C26 cells and HSCs, among others, was correlated 
with a reduction in tumor development (Supplementary Fig. 
2). Therefore, the recruitment of LSECs to nascent foci may 
be abrogated, thus impairing tumor angiogenesis. Further-
more, myeloid-derived suppressor cells (MDSC), an immune 
population able to impair immune response, are accumulated 
during liver metastasis (Burga et al., 2015; Benedicto et al., 
2018), and favor CRC liver metastasis and angiogenesis (Lin 
et al., 2019; Vetsika et al., 2019). It has been documented that 
both VEGF and PGE2 drive the accumulation and differentia-
tion of MDSCs in the tumor microenvironment (Obermajer et 
al., 2011; Horikawa et al., 2017). Both PGE2 and VEGF levels 
are reduced in CLX-treated mice, which, in turn, may prevent 
MDSC recruitment and differentiation, as reported in several 
cancer models upon COX-2 inhibition (Veltman et al., 2010; 
Fujita et al., 2011; Xu et al., 2014). Moreover, activated HSCs 
drive the accumulation of MDSC during liver cancer through 
COX-2 (Xu et al., 2016). We hypothesize that CLX treatment 
may block this recruitment into the liver of this protumoral cell 
population, slowing down tumor growth.
Regarding stromal cell interaction, HSCs and macrophages 
are key players that drive several steps in the development of 
liver metastasis (Olaso et al., 2003; Keirsse et al., 2018). Thus, 
























Fig. 7. Tumor COX-2 is upregulated during early stage of liver colonization. Upon tumor cell/LSEC interplay, ICAM-1 stimulates COX-2 in-
crease and PGE2 secretion by CRC cells. COX-2 mediates the secretion of promigratory factors for LSECs, HSCs, and macrophages favor-
ing the creation of a protumoral tumor microenvironment. Moreover, HSC COX-2 supports tumor growth, promoting LSEC migration, tumor 
cell proliferation, and migration. Therefore, the ICAM-1-mediated increase in COX-2 arises as a promoter of liver metastasis in CRC.
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sion. COX-2 inhibition significantly reduced the recruitment 
of HSCs and macrophages into metastatic foci. Interestingly, 
COX-2 blockade inhibited ICAM-1-mediated augmentation of 
the stromal reaction. We hypothesize that reduced protumoral 
stimulus generated by both tumor cells and tumor-activated 
stromal cells impairs the recruitment of HSCs and macro-
phages. In fact, the observed reduction in VEGF levels in the 
blood plasma may explain the reported reduction in ASMA-
expressing cell recruitment into the metastatic foci as VEGF 
mediates both the migration and proliferation of HSCs (Olaso 
et al., 2003; Liu et al., 2009). Regarding the implication of 
macrophages in the liver’s reaction to tumor cell colonization 
and growth, the decreased inflammatory response generated 
by reduced tumor growth may account for the impaired F4/80-
positive cell infiltration in metastatic foci. Furthermore, acti-
vated HSCs constitute a significant source of CXCL12, which 
mediates the recruitment of CXCR4-expressing MDSCs (Xu 
et al., 2019) into the liver. In line with this process, cancer-
associated fibroblasts (CAFs) drive the accumulation and dif-
ferentiation of monocytes into M2 macrophages, which may 
also occur in the liver (Li et al., 2019). 
The obtained data support the role of tumor COX-2 as a 
mediator in the early steps of liver metastasis, which both 
increases the response of tumor cells to ICAM-1 and drives 
the prometastatic phenotype of HSCs. COX-2 amplifies the 
creation of a favorable niche in the liver, leading to metastatic 
growth. These results uncover novel roles for COX-2 while 
suggesting a combination approach with chemotherapy drugs 
to reduce metastatic lesions of CRC.
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